| アブストラクト | The relevance of biological therapies for an increasing number of conditions is on the rise. Following the expiry of the initial period of market exclusivity, many of these successful therapies have seen the arrival of biosimilars on the market. The clear identification of the precise medicine responsible for an adverse drug reaction (ADR) report is an important element for pharmacovigilance, allowing timely detection of potential product-specific safety signals. We looked at the identifiability of biologicals up to the level of commercial product name in ADR reports received from European clinical practice between 2011 and December 2019. A good level of identification (91.5%) was observed overall, but at the same time a downward trend was observed in the last 5 years. This reduction in the level of identifiability of biological products (originators and biosimilars) at the commercial name level in general was driven by five widely used substances, whereas the identification of all other biologics stayed consistent over time (at over 90%). We observed that those five substances were used mostly within oncology. The introduction of the first biosimilar in the market did not appear to affect their identifiability. These results show that although the general level of identification at the commercial product name level in ADRs in Europe is robust and generally stable over time, decreasing trends can be down to a few commonly used substances, which need to be monitored to reverse the trend. |
|---|
| ジャーナル名 | Clinical pharmacology and therapeutics |
|---|
| 投稿日 | 2021/9/3 |
|---|
| 投稿者 | Correia Pinheiro, Luis; Giezen, Thijs J; Wolff-Holz, Elena; Weise, Martina; Laslop, Andrea; Hidalgo-Simon, Ana |
|---|
| 組織名 | European Medicines Agency (EMA), Amsterdam, The Netherlands.;Foundation Pharmacy for Hospitals in Haarlem, Haarlem, The Netherlands.;Medicines Evaluation Board, Utrecht, The Netherlands.;Biosimilar Medicinal Products Working Party (BMWP), European Medicines Agency,;Amsterdam, The Netherlands.;Bundesinstitut fur Arzneimittel und Medizinprodukte, Bonn, Germany.;Paul-Ehrlich-Institut, Langen, Germany.;Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency,;Bundesamt fur Sicherheit im Gesundheitswesen (BASG), Vienna, Austria. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34472087/ |
|---|
